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Antibiotic resistance is increasing worldwide and becoming a serious problem for the treatment of patients and also affecting their economy. One instance of bacteria that is resistant to the antibiotic is Methicillin-Resistant Staphylococcus aureus (MRSA). MRSA infections are fatal and even deadly. Some MRSA strain has shown resistance towards currently available antibacterial agents. To overcome this, we need new compound alternatives. One of the compounds currently being developed is xanthone derivatives. Xanthones can be found in many kinds of plants, including Garcinia mangostana , in which the active compounds are mangostanin 
and α-mangostin. Xanthones is effective against several types of Gram-positive and Gram-negative bacterias, including Staphylococcus species. Some studies have shown that xanthone derivatives are effective against Staphylococcus aureus, including MRSA. One of the proposed mechanisms of xanthone’s antibacterial activity is the involvement of the bacteria’s cytoplasmic membrane. Xanthone amphiphilic compounds are capable of disrupting bacterial membrane through a mechanism called interfacial activity models. Xanthone can also act as the antioxidant and by inducing the release of lipoteichoic acid (LTA) from the cell wall of MRSA. LTA is the main constituent of the cell wall of Gram-positive bacteria, which are covalently bonded to the outside of peptidoglycan. This structure is important for cell division and bacterial osmotic protection. Thus, it is believed that the mechanism of action of xanthones involved damaging bacterial cell membrane.
Resistensi antibakteri yang semakin meningkat menjadi masalah serius dalam penanganan pasien dan 
berdampak secara ekonomi. Bakteri yang mengalami resisten di antaranya adalah Methicillin-Resistant 
Staphylococcus aureus  (MRSA). Infeksi oleh MRSA dapat berakibat fatal hingga menimbulkan kematian. 
Saat ini MRSA sudah mulai menunjukkan adanya resistensi terhadap beberapa antibakteri yang tersedia. 
Untuk mengatasi hal tersebut, diperlukan  alternatif senyawa baru yang dapat mengatasi infeksi  MRSA. 
Salah satu senyawa yang dikembangkan adalah turunan xanthone. Xanthone terdapat pada beberapa 
macam tanaman, di antaranya Garcinia mangostana dengan senyawa aktif mangostanin, α-mangostin. 
Xanthone efektif terhadap beberapa jenis bakteri Gram positif dan Gram negatif. Genus Staphylococcus 
termasuk bakteri Gram positif yang sensitif terhadap senyawa xanthone. Beberapa penelitian menunjukkan 
bahwa selain efektif terhadap Staphylococcus aureus, xanthone juga potensial untuk digunakan pada 
MRSA. Senyawa xanthone amphiphilic mampu mengganggu membran bakteri melalui mekanisme yang 
disebut interfacial activity model. Mekanisme lain diduga bekerja dengan cara menginduksi pelepasan 
lipotheicolic acid (LTA) dari dinding sel MRSA. LTA adalah penyusun utama dinding sel bakteri Gram positif, 
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yang berikatan secara kovalen dengan bagian luar 
peptidoglikan, yang penting dalam pembelahan sel 
dan proteksi osmotik bakteri. Dengan demikian, 
diduga bahwa mekanisme kerja xanthone 
melibatkan kerusakan dinding sel dan membran sel 
bakteri.
INTRODUCTION
1. Antimicrobial resistanceAntimicrobial resistance especially antibacterial is not a new-found phenomenon, and it has become an increasingly serious health concern. World Health Organization (WHO) stated that antimicrobial resistance us one of the most vital public health problem.1  Data has shown that the yearly mortality rate caused by antimicrobial resistance infections are 23.000 in America, 25.000 in the Europe Union, and 58.000 in India.2 These findings have stimulated a lot of global surveillance action.1,3-5Antimicrobial resistance has caused a 
significant delay of effective treatment course for infectious diseases, and often times even caused patients to fail to receive proper treatment. Many advancements in the medicine world, for instance, the presence of chemotherapy for cancer and organ transplantation, are very dependent on an effective anti-infection. This also has implications not only medically but also economically. In addition to that, other disadvantages that can not be counted, like chronic pain, hindrance in daily activities, and psychological costs.6 The estimation of yearly expenses caused by antimicrobial resistance in America had reached 55 billion dollars and in Europe 1,5 billion euro, in which the 900 million euro was due to inpatient treatment and loss of productivity at work.4,7General data in some countries showed that the incidence of antimicrobial resistance including multidrug resistance (MDR) both in the hospital and community settings are constantly increasing.6 This resistance is complex and multifactorial. Nonetheless, irrational antimicrobial usage is still thought to be the most important factor.7 Unnecessary  antibacterial prescription, as well as unstandardized dosage, 
contributes 50% overall antimicrobial usage.4 The lack of regulation of antimicrobial utilization in other non-medical sectors, for instance, farming, is causing this issue to become more complex.7 The discovery of antibacterial as one kind of antimicrobial agent that can eradicate bacterial were considered a revolution of health sector during the 20th centuries.8 The history of antibacterial agents begun in 1928, when Alexander Fleming accidentally discovered 
penicillin for the first time. In 1929, Fleming 
wrote about penicillin for the first time, however at that time penicillin was not used for medical purposes, until a team from Oxford University did so in the 1940s.9 In the next phase, the precence of many kinds of antimicrobial agents had saved so many lives from infectious diseases, which in the pre-antibiotic era was incurable.10The existence of antimicrobial agents is limited and non-renewable, which human beings will always need.10 This had been proven in 1947, only 4 years after penicillin was mass-produced, 
Staphylococcus aureus (S. aureus) resistance to penicillin had been reported.8 Bacterial can develop antibacterial resistance through several mechanisms, for instance through inhibiting pathway, modifying site of action, 
efflux mechanism, drug-target mutation, and 
membrane permeabilities modification.11Considering the importance of antibacterial agents in the treatment process and its irreplaceable role, guidelines for rational use of antibacterial was made, one of which is published by Infectious Diseases of  Society of America (IDSA) and Society of Healthcare Epidemiology of America.7 Other guidelines include those published by The Antibiotic Stewardship and Resistance Working Groups of the International Society for Chemotherapy, for the public settings and hospital settings.12,13 These guidelines are a form of strategical effort to optimize the effective use of antibacterial, lessen the occurrence of side 
effects, minimizing treatment cost, and finally preventing bacterial resistance.7The increase of antibacterial resistance happens not only inside hospital settings but 
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also in the community. Some of this resistance are different depending on the region 5. In western countries, methicillin-resistant Staphylococcus 
aureus (MRSA), Vancomycin-resistant enterococci (VRE), Escherichia coli and β-lactamase 
Klebsiella pneumonia (ESBL), and carbapenem-
resistant Enterobacteriaceae (CRE) are the most commonly seen. Among those antibacterial-resistant bacterias, MRSA is the most common pathogen found in the hospitals in Asia.8
2. Methicillin-resistant S. aureus (MRSA)Among all gram positive bacterias, S. aureus draws more public interest due to a very rapid resistance occurrence both in the hospitals and communities. The spreading of its resistant strain was also very massive.10 This bacteria 
was first reported to be resistant to penicillin only 4 years after penicillin mass-production.8 Before 1950, S. aureus had been resistant to penicillin-alternatives antibacterial like 
erythromycin, streptomycin, and tetracycline. In  1959, methicillin was found as an alternative for infections caused by S. aureus. However, only two years after methicillin was introduced, an occurrence of resistance was reported.14 The high incidence of infection caused by MRSA demands penicillin-alternative medicines as treatment options, which price are far more expensive.1
2.1 EpidemiologyOn the early reports, MRSA was still limited in hospital settings and rarely occurred in the community. The occurrence of resistant-
strain was first reported in the early  1990s in Australia, and after a few years occurred in the Europe, United State, Latin America, and Asia.14 Infections caused by MRSA are the most commonly found infection in hospital settings, attacking approximately 80.000 individuals every year, 11.000 of which are deadly. This infection usually occurs during hospital stay or not long after hospitalization.4 In Asia, between 2004-2006, an infection caused by MRSA in hospital setting was 67,5% and in the community was 25,5%.15 In the US, until late 1980s MRSA infections in the hospital was around 8-22%, 
however, this number increased by 60% in 2003. 
Similar findings were found in Latin America and 
other Asia Pacific region, where in early 2000s MRSA infection in hospital settings reached more than 50%.14Overall, the occurrence of MRSA infections in a various country are decreasing for around 30%, however, there are still some health service facilities with high incidence level, amounting to 50% or even 60%.14 In contrary to the decreasing occurrence of MRSA infections inside the hospital, within the last decade, MRSA infection in the community (individuals who are not exposed to hospital settings) are increasing. The pattern of this infections is different from those in the hospital setting, including the strain of the MRSA.4 The types of MRSA  in the community have different genotypes from the resistant strain in the hospital and are still sensitive to some beta-lactam antibacterial, for instance, 
gentamycin, ciprofloxacin, and trimethoprim-sulfamethoxazole.14 The occurrence of multiple drug resistance (MDR) to MRSA in the community is lower than in the hospital.15 
2.2 The mechanism of Resistance
 MRSA is resistant to almost all β-lactam antibacterial, which  include group of penicillin (penicillin, dicloxacillin, nafcillin, oxacillin, all.) and cephalosporin.16 This group of antibacterial works by inhibiting the synthesis of cell wall especially during the formation of peptidoglycan, which made the bacterial cell walls to become 
vulnerable and lysis easily. The β-lactam groups contribute as a pseudosubstrate that assimilates the active sides of bacterial penicillin-binding protein (PBP), thus inhibiting the cross-linking process of peptidoglycan polymer.17 Most S. 
aureus resistance against β-lactam antibacterial is due to PBP changes.18The resistance of MRSA is believed to be caused by mec (mecA, mecB, dan mecC) gene, 
that code a specific protein called PBP2A as a form of PBP changes. PBP2A is an additional PBP excluding the four existing PBP (PBP 1-4) in native S. aureus.18 The affinity of PBP2A 
against β-lactam antibacterial is lower than S. 
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aureus endogen PBP and can substitute the function of PBP.19 The lack of inhibition against peptidoglycan cross-linking polymers would keep the bacterial cell walls intact even with 
the administration of β-lactam.17 This condition will defend the survival of MRSA in a high 
concentration β-lactam environment.18 The mecA gene is located on the Staphylococcal 
cassette chromosome (SCC)mec, which is a mobile genetic element (MGE) in the Staphylococcus 
genus that can interchange between species.20 The acquisition of bacterial resistance happens through excision and integration with the 
mediation ofspesific recombinase gene called ccrAB and/or ccrC, and after that the SCCmec would be integrated into Staphylococcus chromosome.16 Therefore, it can be concluded that SCCmec has a substantial role in virulence coding, immune escape mechanism, and antibacterial resistance gene.21
Figure 1. The scheme of Resistency in MRSA.22Currently, there are eleven types of SCCmec (type I-XI) in various countries, with different intrinsic characteristic and predomination among countries.16 For instance, SCCmec III is the most dominant types in countries like Arab, Indonesia, Thailand, Vietnam, China, Singapore, and India, which is also a type that showed resistance against cefoxitin, cephazolin, gentamycin, erythromycin, tetracycline, clindamycin, and cotrimoxazole.23 Since 1996, the occurrence of infections caused by MRSA has increased, and accompanied with decreasing sensitivity for vancomycin (vancomycin-intermediate S. aureus) in the Europe, Asia, and America. Furthermore, in 2002, there was also reports about vancomycin-resistant S. aureus/VISA.24 VISA was also found to be resistant to teicoplanin, an antibacterial similar to vancomycin, a glycopeptide antibacterial that inhibits the synthesis of cell wall.25 Due to these 
similarities, the term glycopeptide-intermediate S. aureus/GISA is more preferred.24 Decreasing sensitivity of S. aureus against glycopeptides antibacterial is mediated by tcaA, which is a gene whose expression would affect the sensitivity of MRSA against vancomycin and teicoplanin. When the gene expression is high, S. aureus will be more sensitive towards vancomycin and teicoplanin, and vice versa.26 
2.3 Methicillin-susceptible S.aureus(MSSA) 
versus Methicillin-resistant S. aureus 
(MRSA) Until now, the difference in pathogenicity and virulence of MSSA and MRSA are still poorly described. Clinical data showed that hospitalization period, mortality rate, and treatment cost is higher in MRSA infection when compared to MSSA.20 The general comparison of clinical aspects between MRSA and MSSA can be seen in Table 1.
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Table 1. The comparison of clinical aspects between MSSA and MRSA
Parameter MSSA MRSA p value Reference point1. Outcome patients n = 433 n = 382 Significance p<0,001• Patients died due to infection 22 (5,1%) 45 (11,8%) < 0,001 27• Patients with bacteremia and without spreading infection
∎ Total patients 406/433 (93,8%) 355/382 (92,9%) < 0,001 27
∎ Death 12/406 (3,0%) 35/355 (9%) < 0,001 272. Local Patients n = 80 n =159 Significance p<0,01• abscess 23 (28,7%) 80 (50,3%) < 0,01 28• pneumonia with complication 2/13 (15,4%) 12/17 (70,6%) < 0,01 283. Virulency, SCCmec subtype, and antibacterial resistance factor n = 88 n = 104 Significance p<0,05• SCCmec type III 28 (31,8%) 67 (64,4%) 0,001 23• entE 63 (71,6%) 88 (84,6%) 0,019 23• etb 14 (15,9%) 1 (1%) 0,000 23• vancomycin resistance 3 (3,4%) 31 (29,8%) 0.001 23• resistance gene distribution qacA/B 24/200 (12%) 186/297 (63%) significance 29Note:MRSA = methicillin-resistant Staphylococcus aureus, MSSA = methicillin-susceptible Staphylococcus aureus, SCCmec = Staphylococcal cassette chromosome mecThis table shows the clinical importance of MRSA compared to MSSA, where MRSA is 
significantly causing longer hospitalization period, higher mortality rate, and more expensive treatment cost. This indicates how important an effective treatment against MRSA really is so that morbidity can be reduced. 
2.4 Alternative treatment for MRSA
The high resistance of MRSA against β-lactam is causing an emerging needs of second-line medicine. The alternative therapy for MRSA based on WHO standard includes linezolid (the 1970s) and daptomycin (1980s).2 Except for these two medicines, another alternative like tigecycline, telavancin, and ceftaroline is also 
still being developed.30 Vancomycin which was previously used as the drug of choice for MRSA is now being substituted due to increasing resistance. Unlike 
β-lactam antibacterial, the resistance of S. aureus against vancomycin and other glycopeptides antibacterials needed 40 years to develop.14 This drug also needs a therapeutic drug monitoring (TDM) in its usage due to high nephrotoxicity.30Resistance against alternative antibacterial agents like linezolid and daptomycin had been reported before. Resistance against linezolid caused by RNA subunit 23S methylation due 
to chloramphenicol/florfenicol resistance (cfr) gene, would cause an alteration of ribosomal binding.30 The cause of resistance to daptomycin 
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is an enzyme called lysyl- phosphatidylglycerol (LPG) synthetase, that increases the synthesis of total LPG, a similar mechanism with resistance towards vancomycin.14 Antibacterial that can still be used for MRSA with the decrease of sensitivity towards vancomycin, daptomycin, and linezolid, include quinupristin/dalfopristin, TMP-SMX, and telavancin, both as single drugs or combination with other antibacterial.31The occurrence of resistance towards alternative antibacterials for MRSA implicates the need for further development of other compounds that targets MRSA increasing occurrence. One potential compound that can be developed as antibacterial agent for MRSA is xanthone.
3. The potential of xanthone development 
as an  anti-MRSA compound
3.1 Xanthone in vitro analysis of anti-
MRSA activity Discovering new treatment course can be done by utilizing traditional herbal medicine 
or its synthetic compounds. Some new anti-infection drugs that originated from the nature has been approved by the Food and Drug Administration (FDA) since 2005, for instance doripenem, tigecyclin, telavancin, retapamulin, and monobactam aztreonam.11 Xanthone derivatives compounds are good antimicrobial candidates, due to their antibacterial, antiviral, and antifungal characteristic. Not only as an antimicrobial spectrum, xanthone is also effective as antitumor, antioxidant, antiallergy, and anti-
inflammatory.32 Xanthone derivatives (9H-xanthene-9-one) are a group of oxygen-containing heterocyclic compounds (Figure 2). The main structure of xanthone includes a planar tricyclic frame where one pyran ring fused with the two accompanying 
rings thus called dibenzo-γ-pyrone.33 Natural xanthone can be divided based on its additional binding groups, for instance, simple oxygenated xanthone, glycosylated xanthone, prenylated xanthone, and so on.34
Figure 2.The main structure of xanthone33As an antibacterial, xanthone is effective against a lot of gram positive and gram negative bacterias. Xanthone-sensitive gram positive bacterial include Staphylococcus, 
Peptostreptococcus, and Streptococcus. Xanthone-sensitive gram negative bacterial include Escherichia coli and Pseudomonas aeruginosa 34. Some studies showed that xanthone is not only effective against Staphylococcus aureus, but also potential against MRSA. Natural in vitro activity of xanthone against MRSA is summarized in Table 2.Table 2 shows that the anti-MRSA activities of xanthone are different among plants in Garcinia genus. The best activities are found 
in α-mangostin compound (Figure 3) from Garcinia mangostana with MIC less than 2 µg/mL. While the lowest activity was found in Garcinia staudtii with MIC more than 15 µg/mL. Anti-MRSA activities of natural xanthone depend on its binding functional group. Some functional group that contributes in anti-MRSA properties of xanthone include methoxy in C-7 and hydroxy in C-5 as in Figure 4; H-5, 6-OH, prenyl C-8, as well as dimethyl chromene ring in C-2 and C-3 as seen in Figure 5 ; free prenyl in C-4 and hidroxy in C-5 and C-7 as seen in Figure 6; isoprenyl as seen in Figure 7(40).35,36,40,42 The elimination of isoprenyl group can eliminate anti-MRSA activity.11
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Table 2. Natural activity of xanthone against MRSA
Plants Active compound Method MRSA isolats MIC (µg/mL) Reference
Garcinia 
cowa
garciniacowone macrodilution SK1 2 35cowanol macrodilution SK1 2 35mangostanin microdilution SK1 4 36
Garcinia 
mangostana
α- mangostin macrodilution DM21455 1,56 37
α- mangostin macrodilution clinical isolated 1,95 38
α- mangostin microdilution clinical isolated (9 strain) 6,25-12,5 39
α- mangostin macrodilution DM21455 0,39 119808R 0,78
α- mangostin macrodilution DM21455 0,39 409808R 1,56
Garcinia 
hanburyi
morrelic acid disk diffusion assay SFA300 12,5 (µM) 41
Garcinia 
staudtii
Staudtii xanthone A agar-well-dif-fusion NM* 16 42
Calophyllum 
brasiliense
1,3,5,6- tetrahydroxy-2-(3,3- dimethylallyl)  xanthone
microdilution 3208 (no production of 
β-lactamase) 2
43
80401 (produce 
β-lactamase) 4*NM: not mentioned
Figure 3. The structure of α-mangostin from G. mangostana38
Figure 4. The structure of garciniacowone (a) and cowanone (b) from G. gowa35
(a) (b)
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Figure 5. The structure of mangostanin (compound 11) from G. Cowa36 Figure 6. The structure of staudtii xanthone A (compound 1) from G. staudtii42
Figure 7. The structure of α-mangostin with additional isoprenyl group40Not only that it has high anti-MRSA activity, 
α-mangostin from G. mangostana (AM-0016) also has much lower hemolytic activity (membranolytic) in rabbit’s eritrocytes thus it is not toxic to normal tissue.37 The results from quantitative structure-activity relationship 
analysis of some modified α-mangostin group show that the substitution of N-ethyl group produces better inhibitory activity (MIC 0,39-3,125 µg/mL), while longer natural N-propyl or alkylamin substitution produce lesser anti MRSA activity, with  MIC ≥ 12,5 µg/mL (Table 3). The order of anti-MRSA activity and hemolytic is 
non isoprenyl or non hydrogenized compounds< 
hydrogenized isoprenyl < isoprenyl. This research found that isoprenyl groups has more contribution on anti-MRSA activity, as well as affecting the hemolytic properties.11
3.2 The antibacterial mechanism of 
xanthone compounds against MRSAThe antibacterial mechanism of xanthone derivatives against MRSA is currently still unclear. 
One of the posibility of its target mechanism is through bacterial cytoplasmic membrane. 
α-mangostin induces potential membrane disipation teice faster in two times Minimum Inhibitory Concentration (MIC), and thus causing a leakage of bacterial intracellular components.37 Amphiphilic xanthone compound can disrupt bacterial membrane through a mechanism called interfacial activity model.11 This mechanism depends on a balance between hidrophobik and electrostatic interaction of peptides, water, and lipid, and is also the basic mechanism of antimicrobial peptide/AMP.44Model interfacial activity contributes in the development of new AMP antibacterial agents, especially for bacterias who has been resistant. Most AMP works by damaging bacterial cell membrane so that bacterias are more prone to antibacterial agents.45 This is why the utilization of xanthone is combined with other antibacterials that has been proven effective against MRSA and are sinergistic in nature.39  Xanthone is also presumed to work as anti-
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MRSA by inducing the release of lipotheicolic acid (LTA) from MRSA cell wall. LTA is the main compound in the cell wall of Gram positive bacterias that bind convalently with the outer part of peptidoglikan which is important in cell  protection.46 The damage of LTA will ease the work of other antibacterial agents to eradicate target bacterias. Xanthone ability as an antioxidant is also presumed to contribute to its role against MRSA.47 An antioxidant compounds are able to interact with the cell membrane of targeted microorganism, through its ability to bind with extracellular protein, soluble protein, and bacterial cell wall. MRSA as a Gram positive bacteria will be easier to eradicate by antioxidant compound because it only has one layer cell wall, while Gram negative bacteria has more layers of cell walls.48 Nonetheless, mamalian cell walls can also be affected by antioxidant, thus an anlysis of Xanthone’s possible toxicity in normal cells is needed, for instance in erythrocyte. All the mechanisms mentioned above leads to bacterial cell wall and membrane damage, which highly depends on Xanthone ability to penetrate 
the cell wall. Thus,currently,  the development of xanthone as anti MRSA is more directed to design and development of smaller molecules with higher membran selectivity to lessen the toxicity against normal mamalian cells.49 Some efforts that has already been done is adding a lipophylic functional groups, like those in xanthone amphiphilic compound, which produce higher anti MRSA activity with lower membrane selectivity and lower toxicity.11
CONCLUSIONThe development of MRSA in hospitals and community settings, as well as the emergence of resistancu against currently used anti MRSA antibacterials (linezolid and daptomycin) triggers continuous new research on possible anti MRSA, including xanthone. Various in vitro studies showed the ability of xanthone derivates to inhibit the growth of MRSA and its selective antibacterial nature (non-toxic to normal cells). The mechanism of action of xanthone derivates as anti-MRSA is still unclear, but it is presumed to involve bacterial cytoplasmic damage and 
Table 3. α-mangostin compound from G. mangostana and its selectivity
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through antioxidant activity. By discovering the structures that contributes in antibacterial activities of xanthone derivates,  further xanthone development as antibacterial is possible by modifying those structures, for instance,  by adding a lipophylic functional groups . 
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